Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal enoxaparin against COVID-19
NL-OMON28133Recruiting
- Sponsor
- ZonMw
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of enoxaparin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ZonMw. Primary endpoints: SARS-CoV-2 pseudovirus binding to nasal epithelial cells and Authentic SARS-CoV-2 binding to nasal epithelial cells. Started Jan 2021; status: recruiting.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON28133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28133.